Evidence map›Paper›PMID 26553159›Full record

Trial reportCNS & neurological disorders drug targets2016

The Effects of Testosterone Supplementation on Cognitive Functioning in Older Men.

Eka J Wahjoepramono, Prita R Asih, Vilia Aniwiyanti, Kevin Taddei, Satvinder S Dhaliwal, Stephanie J Fuller, Jonathan Foster, Malcolm Carruthers, Giuseppe Verdile, Hamid R Sohrabi and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in CNS & neurological disorders drug targets, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Testosterone, cognitive decline and dementia in ageing men.Reviews in endocrine & metabolic disorders · 2022
    Review
  9. The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.International journal of molecular sciences · 2022
    Review
  10. Article
  11. [Testosterone and Alzheimer's disease].Problemy endokrinologii · 2022
    Article
  12. Impact of Testosterone on Alzheimer's Disease.The world journal of men's health · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Androgen Therapy in Neurodegenerative Diseases.Journal of the Endocrine Society · 2020
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Eka J Wahjoepramono
Prita R Asih
Vilia Aniwiyanti
Kevin Taddei
Satvinder S Dhaliwal
Stephanie J Fuller
Jonathan Foster
Malcolm Carruthers
Giuseppe Verdile
Hamid R Sohrabi
Ralph N MartinsSchool of Medical Sciences, Faculty of Computing, Health, and Science, Edith Cowan University, Joondalup, WA, Australia. r.martins@ecu.edu.au.
Edith Cowan University · AUUniversity of Western Australia · AUCurtin University · AUHollywood Private Hospital · AUPelita Harapan University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reduction in testosterone levels in men during aging is associated with cognitive decline and risk of dementia. Animal studies have shown benefits for testosterone supplementation in improving cognition and reducing Alzheimer's disease pathology. In a randomized, placebo-controlled, crossover study of men with subjective memory complaint and low testosterone levels, we investigated whether testosterone treatment significantly improved performance on various measures of cognitive functioning. Forty-four men were administered a battery of neuropsychological tests to establish the baseline prior to being randomly divided into two groups. The first group (Group A) received 24 weeks of testosterone treatment (T treatment) followed by 4 weeks washout, and then 24 weeks of placebo (P); the second group (Group B) received the same treatments, in reverse order (Placebo, washout, and then T treatment). In group A (TèP), compared to baseline, there was a modest (1 point) but significant improvement in general cognitive functioning as measured by the Mini Mental State Examination (MMSE) following testosterone treatment. This improvement from baseline was sustained following the washout period and crossover to placebo treatment. Similar Mini Mental State Examination (MMSE) scores were observed when comparing testosterone treatment with placebo. In group B (PèT) a significant increase was observed from baseline following testosterone treatment and a trend towards an increase when compared to placebo treatment. Improvements in baseline depression scores (assessed by Geriatric Depression Scale) were observed following testosterone/placebo treatment in both groups, and no difference was observed when comparing testosterone with placebo treatment. Our findings indicate a modest improvement on global cognition with testosterone treatment. Larger clinical trials with a longer follow- up and with the inclusion of blood and brain imaging markers are now needed to conclusively determine the significance of testosterone treatment.

Indexed as

Dietary SupplementsAgedAged, 80 and overAnalysis of VarianceAnimalsApolipoprotein E4Cognition DisordersDepressionDose-Response Relationship, DrugDouble-Blind MethodEstradiolFollow-Up StudiesHumansMaleMental Status ScheduleMiddle AgedApolipoprotein E4EstradiolTestosterone

Identifiers

PMID26553159
PMCPMC5078598
OpenAlexW2157540948

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.